Hematopoietic Cell Transplantation for Hodgkin's Disease

Autologous and allogeneic hematopoietic cell transplantation (HCT) for Hodgkin's disease are covered when the patient meets the transplanting institution's selection criteria (or, if none exist, when the patient is in primary induction failure or beyond first remission and has no serious organ dysfunction); non‑myeloablative (reduced‑intensity) allogeneic HCT is covered for relapsed or primary refractory HD only if the patient is eligible for conventional allografting. Tandem (sequential) transplants are excluded as experimental/investigational, and CPT/HCPCS codes are reimbursed only when the policy's selection criteria are satisfied.

"Autologous Hematopoietic Cell Transplantation For the treatment of Hodgkin's disease (HD) when the member meets the transplanting institution's selection criteria."

Sign up to see full coverage criteria, indications, and limitations.